Headline
Rio Tinto and Standard Chartered lead a broadly resilient H1 reporting slate, but Middle East risk overlays and softening insurance/credit conditions run beneath the surface.
What UK Plc said today
No profit warnings in the operating universe today. The tone across large-caps was firmly constructive. STAN raised full-year guidance to RoTE >12% and mid-range 5-7% income growth on a "record" H1, hiked the interim dividend 66% to 20.4c and added a $1bn buyback STAN. RIO posted a 28% jump in underlying EBITDA to $14.8bn, 75% rise in FCF, and lifted the interim dividend 43% to $3.4bn, with 2026 production guidance held RIO. SGE accelerated to +11% nine-month revenue (organic +10%) and reiterated FY26 organic growth above 9%.
Consumer and industrial mid-caps mostly reaffirmed: GRG delivered +7.2% H1 revenue with 22.9% operating profit growth and confirmed the H2 cost headwind previously flagged; FRAN reaffirmed £35.9–38.0m adjusted EBITDA; BREE held guidance despite a fifth consecutive year of GB volume decline; NICL reaffirmed and lifted the interim dividend 34.7%. Trading updates from ABDX (+31%), AGY (+9%, double-digit guided for FY27), CDGP (+19%) and ECOR (+60%) all skewed "ahead".
Two clear negatives. RAT lowered its Q4 operating margin target from 30.0% to 28.7% after the FCA Skilled Person Review, with c.£60m of costs over two years and cessation of cash portfolio fees (c.£9m H2 headwind) RAT. JSE cut 2026 production guidance to 16–18 kboepd from 18–21 kboepd. AML reported a 38% revenue lift but pushed net interest guidance up to c.£160m and remains loss-making with net debt at £1.54bn.
Statistical releases
- ONS Population estimates for England and Wales, mid-2025 — headline demographic reset feeding into consumer, housing and fiscal models.
- ONS Estimates of the very old, including centenarians, 2002–2025 — long-run ageing data relevant to pensions and healthcare demand.
- ONS Workless households for regions across the UK, 2025 — regional labour market slack indicator.
- ONS Weekly deaths, England and Wales, week ending 17 July 2026 — routine mortality release.
- ONS Impact of hospitalisation for sepsis on earnings/employment, April 2014–December 2024 — narrow labour-economics study.
Policy / monetary
[BoE] nothing today. HMT released the July 2026 Public Spending Statistics outturn — the key fiscal read of the day — plus updated Orange Book risk-management guidance and Whole of Government Accounts 2025-26 guidance for preparers. No new policy direction, but the spending outturn feeds directly into borrowing arithmetic ahead of the autumn fiscal event.
Themes
Middle East risk is being explicitly priced in. STAN raised its downside conflict scenario weighting from 41% to 60% and booked $234m of overlays; CRE noted current losses are immaterial but flagged Middle East and Ukraine in forward statements; VALT warned unit costs will land at the upper end of guidance on geopolitical pressure; HSW cited a ~3% transactions hit from Middle East disruption; IKA added conflict inflation to its risk register.
Capital return is broad-based despite the caution. Dividend hikes at STAN (+66%), NICL (+34.7%), SHC (+16%), BREE (+5%), FRAN (+9%), RAT (+3.2%), buybacks at STAN ($1bn new) and HSW (concluded), plus RIO's 50% payout ratio — cash returns are being prioritised even as management commentary turns more cautious.
Regulatory and legal drag is real for financials. RAT's FCA Skilled Person Review is the sharpest example, IPF's CJEU judgment on credit-fee interest is flagged as "uncertain", and PTSB booked €11m of costs on its BAWAG sale process.
Watch
- DGE preliminary FY26 results — Thursday 6 August 2026, 11am UK.
- DEC Q2 2026 results — 5 August 2026.
- ALT FY26 results now expected "the following week" (early August 2026).
- IPF Bidco scheme effective date expected 4 August 2026; 15p special dividend.
- PTSB BAWAG shareholder vote tomorrow, 30 July 2026.
- IDHC mandatory offer closes 12 August 2026.
- LIKE general meeting 14 August 2026 on £30.5m fundraising.